Beta‐amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. Issue 7 (21st January 2016)

• Record Type: Journal Article
• Authors: Clark, Lindsay R.; Racine, Annie M.; Koscik, Rebecca L.; Okonkwo, Ozioma C.; Engelman, Corinne D.; Carlsson, Cynthia M.; Asthana, Sanjay; Bendlin, Barbara B.; Chappell, Rick; Nicholas, Christopher R.; Rowley, Howard A.; Oh, Jennifer M.; Hermann, Bruce P.; Sager, Mark A.; Christian, Bradley T.; Johnson, Sterling C.
• Is Part Of: Alzheimer's & dementia. Volume 12:Issue 7(2016)
• Page Start: 805
• Page End: 814
• Publication Date: 2016-01-21
• Subjects: Alzheimer's disease -- Amyloid imaging -- Preclinical Alzheimer's disease -- Mild cognitive impairment -- Cognition -- APOE; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2015.12.009
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: The present study investigated the relationship between beta‐amyloid (Aβ) and cognition in a late middle‐aged cohort at risk for Alzheimer's disease (AD). Methods: One eighty‐four participants (mean age = 60; 72% parental history of AD) completed a [C‐11]Pittsburgh compound B positron emission tomography scan and serial cognitive evaluations. A global measure of Aβ burden was calculated, and composite scores assessing learning, delayed memory, and executive functioning were computed. Results: Higher Aβ was associated with classification of psychometric mild cognitive impairment (MCI) at follow‐up ( P < .01). Linear mixed effects regression results indicated higher Aβ was associated with greater rates of decline in delayed memory ( P < .01) and executive functioning ( P < .05). Apolipoprotein E ( APOE ) ε4 status moderated the relationship between Aβ and cognitive trajectories ( P values <.01). Discussion: In individuals at risk for AD, greater Aβ in late middle age is associated with increased likelihood of MCI at follow‐up and steeper rates of cognitive decline.